Matinas BioPharma announces collaboration with National Resilience

Matinas BioPharma announced a strategic collaboration with National Resilience, "a technology-focused manufacturing company dedicated to broadening access to complex medicines." The parties have entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids. The parties will closely collaborate on a comprehensive research program comprising the design, formulation, optimization, and in vitro and in vivo testing of these nucleic acid formats in combination with Matinas’ proprietary LNC platform. Terms of the collaboration were not otherwise disclosed. "Our mission is dedicated to unlocking and delivering the full clinical potential of therapies that require intracellular delivery," said Jerome D. Jabbour, Chief Executive Officer and Co-founder of Matinas. "We are thrilled to collaborate with this world-class organization to further demonstrate the capabilities of our LNC platform. We view Resilience as an ideal platform partner and we are excited to work together with them in support of their mission to allow scientists to make their therapies quickly, safely and at scale, so patients around the world can have access to the medicines they need. Importantly, the nature of our collaboration and relationship with